NUTRA PHARMA CORP (NPHC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 300K 600K 900K Q1 '11: 687.9K Q2 '11: 809.4K Q3 '11: 701.3K Q4 '12: 203.3K Q1 '13: 210.9K Q2 '13: 214.9K Q3 '13: 240.6K Q4 '13: 104.8K Q1 '14: 137K Q2 '14: 215.6K Q3 '14: 451.8K Q4 '14: 594.5K Q1 '15: 660.8K Q2 '15: 639.9K Q3 '15: 417.7K Q4 '15: 291.3K Q1 '16: 207.7K Q2 '16: 160.3K Q3 '16: 177.9K Q4 '16: 168.4K Q1 '17: 147.9K Q2 '17: 150.4K Q3 '17: 118K Q4 '17: 121K Q1 '18: 136.5K Q2 '18: 132.7K Q3 '18: 138.6K Q4 '18: 132.1K Q1 '19: 140.9K Q2 '19: 121.8K Q3 '19: 119.8K Q4 '19: 104.4K Q1 '20: 80.2K Q2 '20: 76.2K Q3 '20: 47.6K Q4 '20: 51.9K Q1 '21: 56.8K Q2 '21: 81K Q3 '21: 86.9K Q4 '21: 97.7K Q1 '22: 89.5K Q2 '22: 87.4K Q3 '22: 92.8K Q4 '22: 145.8K Q1 '23: 186.6K Q2 '23: 210.5K Q3 '23: 237.5K Q4 '23: 205.6K Q1 '24: 188.8K Q2 '24: 188.1K Q3 '24: 211.5K Q4 '24: 246.3K Q1 '25: 282.6K Q2 '25: 315.4K Q3 '25: 310.6K Q4 '25: 257.6K Q1 '26: 210.9K Q2 '26: 160.8K Q2 '11 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

-1.2M -800K -400K 0 400K 800K 1.2M Q1 '11: 442.3K Q2 '11: 565.2K Q3 '11: 472.7K Q4 '11: -720K Q1 '12: -796.8K Q2 '12: -1M Q3 '12: -1.2M Q4 '12: 55.6K Q1 '13: 59K Q2 '13: 50K Q3 '13: 73.8K Q4 '13: 63.7K Q1 '14: 95.1K Q2 '14: 173.1K Q3 '14: 365K Q4 '14: 480.2K Q1 '15: 529.4K Q2 '15: 505.9K Q3 '15: 321.6K Q4 '15: 225.5K Q1 '16: 159.5K Q2 '16: 121K Q3 '16: 141.2K Q4 '17: 94.1K Q1 '18: 111.5K Q2 '18: 102.1K Q3 '18: 75K Q4 '22: 249K Q1 '23: 344.3K Q2 '23: 399.4K Q3 '23: 446.2K Q4 '23: 396.5K Q1 '24: 328.6K Q2 '24: 298.8K Q3 '24: 254.5K Q4 '24: 247.3K Q1 '25: 271.3K Q2 '25: 279.8K Q3 '25: 273.7K Q4 '25: 196.6K Q1 '26: 156.5K Q2 '26: 125.7K Q2 '12 Q4 '13 Q2 '15 Q4 '17 Q2 '23 Q4 '24 Q2 '26

Operating Income TTM

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '10: -3.4M Q1 '11: -3.7M Q2 '11: -3M Q3 '11: -3M Q4 '11: -4M Q1 '12: -4.1M Q2 '12: -3.6M Q3 '12: -3.1M Q4 '12: -2.7M Q1 '13: -2.3M Q2 '13: -2.5M Q3 '13: -2.8M Q4 '13: -2.4M Q1 '14: -2.3M Q2 '14: -2.5M Q3 '14: -2.5M Q4 '14: -2.2M Q1 '15: -2.3M Q2 '15: -2.6M Q3 '15: -6M Q4 '15: -5.8M Q1 '16: -5.8M Q2 '16: -5.4M Q3 '16: -2M Q4 '16: -2M Q1 '17: -2.1M Q2 '17: -1.9M Q3 '17: -1.7M Q4 '17: -1.4M Q1 '18: -1.3M Q2 '18: -1.2M Q3 '18: -1.8M Q4 '18: -1.9M Q1 '19: -1.8M Q2 '19: -1.8M Q3 '19: -1.2M Q4 '19: -1.2M Q1 '20: -1.2M Q2 '20: -1M Q3 '20: -987.7K Q4 '20: -924.9K Q1 '21: -1.3M Q2 '21: -1.5M Q3 '21: -1.8M Q4 '21: -2M Q1 '22: -1.8M Q2 '22: -1.7M Q3 '22: -1.4M Q4 '22: -1.9M Q1 '23: -2M Q2 '23: -1.8M Q3 '23: -1.8M Q4 '23: -887K Q1 '24: -783.6K Q2 '24: -820.8K Q3 '24: -839.8K Q4 '24: -878.4K Q1 '25: -932.9K Q2 '25: -1M Q3 '25: -1.2M Q4 '25: -1.5M Q1 '26: -1.5M Q2 '26: -1.6M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '10: -3.1M Q1 '11: -3.4M Q2 '11: -2.6M Q3 '11: -2.7M Q4 '11: -4.4M Q1 '12: -4.8M Q2 '12: -4.4M Q3 '12: -4M Q4 '12: -3.7M Q1 '13: -3.1M Q2 '13: -3.6M Q3 '13: -5.9M Q4 '13: -4.3M Q1 '14: -4.1M Q2 '14: -4.8M Q3 '14: -2.3M Q4 '14: -2.5M Q1 '15: -2.7M Q2 '15: -3.1M Q3 '15: -6.9M Q4 '15: -5.4M Q1 '16: -6.1M Q2 '16: -5M Q3 '16: -1.7M Q4 '16: -3.4M Q1 '17: -3.3M Q2 '17: -3.8M Q3 '17: -4.1M Q4 '17: -4M Q1 '18: -4.1M Q2 '18: -4.3M Q3 '18: -4.3M Q4 '18: -3.9M Q1 '19: -3.3M Q2 '19: -3.6M Q3 '19: -3.1M Q4 '19: -6.6M Q1 '20: -4M Q2 '20: -3.8M Q3 '20: -2.8M Q4 '20: -769.2K Q1 '21: -37M Q2 '21: -32.1M Q3 '21: -17.3M Q4 '21: -13.1M Q1 '22: 25.9M Q2 '22: 21.9M Q3 '22: 7.1M Q4 '22: 8.2M Q1 '23: 2.6M Q2 '23: 2.9M Q3 '23: 2.1M Q4 '23: -1.4M Q1 '24: -1.2M Q2 '24: -1.3M Q3 '24: -1.3M Q4 '24: -1.3M Q1 '25: -2.3M Q2 '25: -1.5M Q3 '25: -1.8M Q4 '25: -2M Q1 '26: -1.1M Q2 '26: -5.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 300K 600K 900K Q1 '11: 245.6K Q2 '11: 244.2K Q3 '11: 228.6K Q4 '11: 879.6K Q1 '12: 851.1K Q2 '12: 792.9K Q3 '12: 708.7K Q4 '12: 147.6K Q1 '13: 151.9K Q2 '13: 164.9K Q3 '13: 166.8K Q4 '13: 41.2K Q1 '14: 41.9K Q2 '14: 42.5K Q3 '14: 86.7K Q4 '14: 114.3K Q1 '15: 131.3K Q2 '15: 134K Q3 '15: 96.2K Q4 '15: 65.8K Q1 '16: 48.2K Q2 '16: 39.3K Q3 '16: 36.7K Q4 '16: 39K Q1 '17: 39.3K Q2 '17: 39.6K Q3 '17: 34K Q4 '17: 26.9K Q1 '18: 25K Q2 '18: 30.6K Q3 '18: 63.6K Q4 '18: 70.3K Q1 '19: 80K Q2 '19: 67.2K Q3 '19: 36.3K Q4 '21: 41.3K Q1 '22: 50K Q2 '22: 101.8K Q3 '22: 133.2K Q4 '22: 162.8K Q1 '23: 200.4K Q2 '23: 219.8K Q3 '23: 203.6K Q4 '23: 177.5K Q1 '24: 148.1K Q2 '24: 86.5K Q3 '24: 85.4K Q4 '24: 84.8K Q1 '25: 108.6K Q2 '25: 148.7K Q3 '25: 159K Q4 '25: 205.1K Q1 '26: 188.1K Q2 '26: 154.6K Q1 '12 Q4 '13 Q3 '15 Q2 '17 Q1 '19 Q4 '22 Q3 '24 Q2 '26

Operating Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q2 '11: -1.5M Q3 '11: -2.1M Q4 '11: -1.9M Q1 '12: -1.6M Q2 '12: -1.1M Q3 '12: -545K Q4 '12: -721.2K Q1 '13: -587.2K Q2 '13: -611.1K Q3 '13: -568.3K Q4 '13: -531K Q1 '14: -557.5K Q2 '14: -434.6K Q3 '14: -205.1K Q4 '14: -148.1K Q1 '15: -174.6K Q2 '15: -698.9K Q3 '15: -885.2K Q4 '15: -1M Q1 '16: -1.2M Q2 '16: -947.7K Q3 '16: -1.2M Q4 '16: -1.4M Q1 '17: -1.5M Q2 '17: -1.5M Q3 '17: -1.3M Q4 '17: -1.1M Q1 '18: -1.1M Q2 '18: -1.2M Q3 '18: -1.1M Q4 '18: -999.9K Q1 '19: -743.1K Q2 '19: -582.7K Q3 '19: -571K Q4 '19: -743.7K Q1 '20: -867.7K Q2 '20: -848.2K Q3 '20: -834K Q4 '20: -878.1K Q1 '21: -1.3M Q2 '21: -1.6M Q3 '21: -1.9M Q4 '21: -1.7M Q1 '22: -1.4M Q2 '22: -1.2M Q3 '22: -942.1K Q4 '22: -762.4K Q1 '23: -597K Q2 '23: -499K Q3 '23: -417.8K Q4 '23: -550K Q1 '24: -628.5K Q2 '24: -535.2K Q3 '24: -432K Q4 '24: -424K Q1 '25: -657.8K Q2 '25: -852.5K Q3 '25: -1.1M Q4 '25: -1.2M Q1 '26: -1.1M Q2 '26: -1M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q2 '12: -1.1M Q3 '12: -545.4K Q4 '12: -721.2K Q1 '13: -587.2K Q3 '15: -887.3K Q4 '15: -1M Q4 '21: -1.8M Q1 '22: -1.5M Q2 '22: -1.3M Q3 '22: -1M Q4 '22: -820.4K Q4 '25: -1.2M Q3 '12 Q1 '13 Q4 '15 Q1 '22 Q3 '22 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15B 30B 45B Q1 '19: 4.1B Q2 '19: 4.6B Q3 '19: 5.1B Q1 '20: 12.3B Q2 '20: 6.6B Q3 '20: 13.1B Q1 '21: 7.1B Q2 '21: 11.8B Q3 '21: 12.7B Q1 '22: 14.5B Q2 '22: 7.5B Q3 '22: 15.6B Q1 '23: 7.6B Q2 '23: 7.6B Q3 '23: 7.6B Q1 '24: 7.6B Q2 '24: 7.7B Q3 '24: 7.7B Q1 '25: 7.7B Q2 '25: 37.7B Q3 '25: 7.8B Q1 '26: 8B Q2 '26: 8.1B Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.15 -0.10 -0.05 0.00 0.05 0.10 0.15 Q4 '10: -0.01 Q1 '11: 0.00 Q2 '11: 0.00 Q3 '11: 0.00 Q4 '11: 0.00 Q1 '12: 0.00 Q2 '12: 0.00 Q3 '12: 0.00 Q4 '12: -0.01 Q1 '13: -0.01 Q2 '13: -0.01 Q3 '13: -0.01 Q4 '13: 0.00 Q1 '14: 0.00 Q2 '14: -0.05 Q3 '14: -0.06 Q4 '14: -0.08 Q1 '15: -0.09 Q2 '15: -0.08 Q3 '15: -0.01 Q4 '15: -0.10 Q1 '16: -0.10 Q2 '16: -0.07 Q3 '16: -0.13 Q4 '16: -0.02 Q1 '17: -0.03 Q2 '17: -0.02 Q3 '17: -0.02 Q4 '17: 0.00 Q1 '18: 0.02 Q2 '18: 0.02 Q3 '18: 0.02 Q4 '18: 0.00 Q1 '19: 0.00 Q2 '19: 0.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.00 Q1 '23: 0.00 Q2 '23: 0.00 Q3 '23: 0.00 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.